Objective: To synthesize gefitinib.
前言： 目的：合成吉非替尼。
If you become pregnant while taking gefitinib, call your doctor.
如果已经怀孕并服用了吉非替尼，请告知您的医生。
Doctor, the profile that you just read is actually for (gefitinib) IRESSA.
医生，刚才您所阅读的简介其实就是(吉非替尼)易瑞沙。
Being female was also significantly associated with response to gefitinib.
病人是女性也与对吉非替尼有反应显著相关。
The acute toxicity of gefitinib up to 500 mg in clinical studies has been low.
急性毒性吉非替尼多达500毫克的临床研究一直很低。
Patients treated with gefitinib would live much longer, with better quality of life, than those treated with cytotoxic chemotherapy.
相对于化疗病人，用吉非替尼的病人将有更好的生活质量以及更长的存活时间。
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
中国的非小细胞肺癌病人中吉非替尼敏感的表皮生长因子受体酪氨酸激酶区域的突变。
Objective To evaluate the efficacy and safety of gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).
目的观察吉非替尼单药治疗对晚期非小细胞肺癌 （NSCLC）老年患者的效果和安全性。
Fortuitously, these drugs also have clinically obvious pharmacodynamic end points-hypertension for bevacizumab and skin toxicity for erlotinib and gefitinib.
例外的是，这些药物也有临床明显的药物副作用——贝伐单抗可致高血压，吉非替尼和厄洛替尼可有皮肤毒性。
However, neither overall survival after the start of antitumor therapy nor progression-free survival after gefitinib therapy was significantly different between groups.
然而，无论是抗肿瘤治疗开始后的整体生存率，还是吉非替尼治疗后无恶化生存率在上述两组病人中并无明显差异。
Background: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.
背景：此前的无对照研究显示肺癌一线治疗联合吉非替尼治疗非小细胞肺癌是有效的。
However, mutant ABCG2 can be less efficient at pushing gefitinib out of cells in the intestine, the researchers noted. A buildup of drug within these cells can cause diarrhea.
研究人员指出，突变的ABCG2降低了肠道细胞“泵出”的功能，使得细胞内的药物逐渐累积从而导致腹泻。
Gefitinib is protein tyrosine kinase inhibitor of a selective EGFR, can block the signal transduction pathway of tyrosine protein kinase, and then promote tumor cell apoptosis.
吉非替尼为一种选择性的EGFR一蛋白酪氨酸激酶抑制剂，能阻断酪氨酸蛋白激酶信号传导通路，从而促进肿瘤细胞凋亡。
Subsequently, we monitored the ligand-dependent HER profiles based on receptor expression, phosphorylation, and dimerization in conjunction with measurements of cellular susceptibility to gefitinib.
接着，我们检测配体依赖的基于受体表达，磷酸化，二聚化的细胞对吉非替尼敏感的机制。
Subsequently, we monitored the ligand-dependent HER profiles based on receptor expression, phosphorylation, and dimerization in conjunction with measurements of cellular susceptibility to gefitinib.
接着，我们检测配体依赖的基于受体表达，磷酸化，二聚化的细胞对吉非替尼敏感的机制。
应用推荐